Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Drug patent plan gets mixed reviews

GlaxoSmithKline's bid to tackle neglected diseases receives a muted response from the rest of the industry.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


Additional information

Additional reporting by Natasha Gilbert

Related links

Related links

Related links in Nature Research

Outlook: Neglected Diseases

Supplement: A World of Science in the Developing World

Commentary: New uses for old drugs

Commentary: Neglected tests for neglected patients

Commentary: Experiments in social responsibility

Special: Malaria killer blow

Related external links

MSF Campaign for Access to Essential Medicines

MSF on patent pools

Drugs for Neglected Diseases Initiative

GSK Access to Medicines site

Institute for OneWorld Health


Knowledge Ecology International

UN Least Developed Countries

Rights and permissions

Reprints and permissions

About this article

Cite this article

Butler, D. Drug patent plan gets mixed reviews. Nature 457, 1064–1065 (2009).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing